Enanta Pharmaceuticals. has filed a patent for compounds of Formula (I) as 17ß-HSD13 inhibitors for treating metabolic diseases and liver conditions. The patent claim includes a compound represented by Formula I or its pharmaceutically acceptable salt or ester. GlobalData’s report on Enanta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Enanta Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Enanta Pharmaceuticals's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20230416268A1) discloses a compound represented by Formula I, along with its pharmaceutically acceptable salts or esters. The compound can be further defined by the presence of specific groups and substitutions, as outlined in the claims. Additionally, the patent covers pharmaceutical compositions containing the compound and a suitable carrier or excipient for administration.
Furthermore, the patent application describes methods for preventing or treating 17ß-HSD13 mediated diseases or conditions in individuals by administering a therapeutically effective amount of the compound. The diseases or conditions targeted include nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver fibrosis, and hepatocellular carcinoma (HCC). The use of the compound in the manufacture of medicaments for these specific diseases is also claimed, emphasizing the potential therapeutic applications of the disclosed compound.
To know more about GlobalData’s detailed insights on Enanta Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
